Ceapro Inc V.CZO

RE:RE:3 Q financials out

[mba123ccu]

prophetoffacts wrote: That was a very strong quarter given CZO only needed to average $2.75 million in revenue in Q3 and Q4 to get to 12% growth for the year as previously noted. The company came in at $3.467 million in revenue. That is 36% revenue growth vs. the previous year for the first nine months. Could be a very strong double digit growth rate for the year.

The company now has over $6.1 million in cash and generated $4.77 million in cash in the first nine months. Not bad for a $53 million market cap company. With the old facility now consolidated into the new facility there should be further increases in cashflow.

COVID program deemed "exciting" with results in near future. NO safety issues reported to date with validates the technology for inhalation. This is more than just COVID; but COVID lung fibrosis alone may be a big market. It looks like they may have had to increase the dose higher than expected to find maximum tolerated dose. Looks very safe. Looking forward to "exciting" results shortly. Could be very soon given Gilles announced the trial for maximum tolerated dose in the last presentation about 1 1/2 months ago.

• "Ongoing PGX-YBG project with McMaster University conducted in parallel for nave and preclinical animal models. To-date, no safety issues have been encountered. The preclinical phase has been extended to identify the maximum tolerated dose. Progress update on this exciting project to be issued in the near future."
• Previous news release:

"Dr. Kjetil Ask added, “If this size optimized PGX-YBG passes the tolerability, safety and therapeutic animal tests that we have already initiated, this material could quite quickly contribute as an immune modulator and anti-fibrotic treatment option for the most severe COVID-19 patients. Additionally, and equally exciting, the possibility of using PGX-YBG as an inhalable carrier of other drugs, would potentially allow the direct delivery of additional treatment options and increase their bioavailability in the lung, while reducing potential side effects.”"

True, all very good numbers especially cash on hand, this can be used for further expansion/research and I think there are lots of good things in the future.